DURHAM, N.C. – FHI 360 welcomes the release of World Health Organization guidelines at the International AIDS Society’s annual research conference recommending lenacapavir (LEN) — a twice-yearly injectable — as an additional PrEP option to prevent HIV.
Hally Mahler, Vice President, Global Programs says:
“Lenacapavir is a game changer for HIV prevention with the potential to prevent millions of HIV infections. Twice yearly injections make highly effective HIV prevention more attainable for many, as they require fewer visits to the clinic and can be used discreetly. Most importantly, expanding the number of available HIV prevention options means individuals at risk of HIV can pick the method that is right for them.
“The release of global guidance at this year’s International AIDS Society conference is a key step toward country-level adoption of the new method.
“Despite the challenging funding environment, the rollout of LEN could significantly transform the global HIV prevention landscape and accelerate progress toward ending AIDS as a public health threat by 2030.
“To live up to its promise, LEN must be available at an affordable price, and the rollout must be guided by coordinated leadership and strategic prioritization. We are looking forward to building on our experience rolling out other HIV prevention methods to support the introduction of LEN.”
FHI 360 has been at the forefront of biomedical HIV prevention research and implementation for more than 20 years. For more information or to arrange interviews, please contact media@fhi360.org.